The study, published in Advanced Materials, describes how the decellularised porcine vaginal ECM (vECM) retained native structural proteins and biochemical cues that promoted cell proliferation, angiogenesis, and collagen remodelling in preclinical models.  

The team used a decellularisation process to strip away all living pig cells, leaving behind a structural and biochemical framework. This material, rich in collagen, glycosaminoglycans, and growth factor-binding sites, was then fabricated into a porous, biocompatible scaffold. In animal testing, implantation of the vECM supported tissue regeneration and improved local vascularisation compared to non–tissue-specific scaffolds.  

Porcine-derived biomaterials are already used in certain approved human implants, such as heart valves, dermal substitutes, and hernia meshes. However, translating this vaginal ECM to human use raises additional considerations. Ethical and cultural objections to porcine products may limit acceptance in some populations, and sourcing from animal tissue requires rigorous screening for pathogens and manufacturing under clinical-grade conditions.  

The authors emphasise that this research is still at an early, preclinical stage. Before any human application, the vECM would need extensive safety and efficacy testing, regulatory review, and possibly the development of alternative sources, such as human donor tissue or synthetic ECM analogues, for patients who cannot or do not wish to receive porcine-derived implants.  

While far from clinical availability, the study highlights the potential of organ- and tissue-specific ECM scaffolds to provide more tailored regenerative cues than generic biomaterials, potentially offering new options in the treatment of vaginal atrophy.